Nan Hu

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Solange Peters, Arnaud Scherpereel, Robin Cornelissen et al. · Annals of Oncology · 2022 · 263 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · Journal of Thoracic Oncology · 2022 · 97 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey.

D Ratnasinghe, Joseph A. Tangrea, Mark J. Roth et al. · PubMed · 1999 · 93 citations

Medicine, Oncology, Pathology +17

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Martin Reck, Tudor–Eliade Ciuleanu, Michael Schenker et al. · European Journal of Cancer · 2024 · 73 citations

Medicine, Oncology, Pharmacology +14

Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy

Jiuyang Liu, Shuran Li, Qin Wang et al. · Blood · 2024 · 71 citations · Full text

Medicine, Oncology, Pharmacology +15